Aroa Biosurgery (ASX: ARX) has announced the publication of the first results from its Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), which has shown significant promise in treating high-risk lower limb reconstruction cases.
The peer-reviewed real-world research is titled “Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A Prospective Study”.
It’s the largest study of lower limb reconstructions with a dermal substitute, showing strong efficacy for the company’s extracellular matrix graft, Myriad.
The study, published in the December issue of Plastic and Reconstructive Surgery – Global Open, marks a key milestone for Aroa, and reinforces the growing potential of Myriad in the surgical limb salvage market.
The study was conducted between May 2022 and April 2023 and involved 130 lower limb defects across 120 patients.
Of these patients, 95% had at least one risk factor for amputation, and 55% had three or more predictive risk factors for amputation.
Lower limb amputation, as we know, can severely impact quality of life, and the five-year mortality rate for patients receiving this amputation can be up to ~50%.
The study found that Myriad Matrix and Myriad Morcells achieved 100% tissue coverage and fill in just 30 days, with only a single application – and crucially, no infections or complications.
The study not only confirms the clinical efficacy of Myriad in lower limb reconstruction procedures, but also highlights significant cost-saving potential.
It demonstrated a cost difference of up to 195% compared to other commercially available dermal substitutes suggesting that Myriad can be a cost-efficient solution for complex lower limb surgeries, where cost containment is a growing priority.
“We are very pleased to see the first clinical evidence emerge from our large prospective MASTRR study,” said Brian Ward, founder and CEO of Aroa.
“The evidence from this study further validates both the efficacy of, and potential cost benefits associated with Myriad use in lower limb reconstruction procedures.
“With a total addressable market of US$225 million for lower limb procedures alone, this represents a considerable opportunity for Aroa.”
Read the full article here
